Last updated: February 4, 2026
What is the core case about?
Zogenix, Inc. filed a patent infringement lawsuit against Lupin Ltd. in the District of Delaware, alleging that Lupin’s proposed generic version of Zogenix’s drug, FINTEPLA (fenfluramine), infringes multiple patent claims. The suit case number is 1:21-cv-01424, filed in 2021.
What patents are at issue?
The case concerns U.S. Patent Nos. 9,709,474 and 10,258,155, both expiring in 2034. These patents cover formulations and methods of use related to fenfluramine for treating seizures associated with Dravet syndrome, a severe form of epilepsy.
What claims does Zogenix make?
- Patent infringement by Lupin’s proposed generic
- Invalidity of the asserted patents due to obviousness or lack of novelty
- Injunctive relief to prevent market entry until patent expiry or invalidation
What is Lupin’s defense?
Lupin contends that the patents are invalid due to prior art that anticipates or renders obvious the claimed formulations. It also disputes the patents’ scope, asserting that the claims lack novelty and are obvious in light of existing pharmaceutical formulations and prior disclosures.
What is the procedural history?
- Filing date: March 2021
- Preliminary motions: Lupin has filed motions to dismiss and for summary judgment challenging patent validity.
- Patent Office proceedings: Inter partes review (IPR) petitions have been filed by Lupin, challenging the patents’ validity.
- Settlement possibilities: No public settlement or licensing agreements disclosed as of the latest update.
What are key legal issues?
- Patent validity: Whether the claimed formulations meet the requirements of novelty and unobviousness under 35 U.S.C. §§ 102, 103.
- Infringement: Whether Lupin’s generic formulations infringe the claims as issued.
- Patent scope and enforceability: Possible scope reductions or invalidations stemming from IPR proceedings.
What is the current status?
As of the latest available information (Q1 2023):
- The district court proceedings are ongoing.
- Lupin’s IPR petitions are pending decision.
- Discovery has commenced, with initial disclosures exchanged.
- No trial date set yet; case is in early litigation stages.
Legal and Market Implications
- Market access: The outcome could delay or expedite Lupin’s ability to launch a generic version.
- Patent enforceability: Validity rulings could narrow patent scope, affecting future patent strategies.
- Regulatory interplay: The case intersects with FDA approvals and patent linkage rules.
Key Takeaways
- The lawsuit targets patent protections for fenfluramine formulations used in epilepsy treatment.
- Lupin challenges patent validity through IPR, indicating a high likelihood of contested validity.
- The case's resolution will influence the timeline for Lupin’s generic entry into the epilepsy drug market.
- Patent validity assessments will hinge on prior art disclosures and obviousness considerations.
FAQs
1. When is a trial likely in this case?
No trial date has been set. The case remains in early stages, with discovery ongoing and procedural motions pending.
2. What impact could invalidation of the patents have?
Patent invalidation could enable Lupin to launch a generic version earlier, affecting Zogenix’s market share and revenues.
3. How does IPR influence the lawsuit?
While not binding on the district court, IPR decisions can inform patent validity arguments and potentially narrow patent scope before trial.
4. Are there similar patent disputes in this market?
Yes, the epilepsy drug market has a history of patent litigation, often centered around formulations, methods of use, and method claims.
5. What strategic options does Zogenix have?
Zogenix can choose to defend patent validity vigorously, pursue settlement, or seek expedited court resolutions if market protection becomes critical.
Cited Sources:
[1] PACER docket entries for case 1:21-cv-01424, Zogenix, Inc. v. Lupin Ltd.
